Amoy Diagnostics

The companion diagnostic for Pfizer's Xalkori identifies 14 ROS1 gene fusions by analyzing tumor messenger RNA from human tumor tissue or body fluids.

AmoyDx's molecular diagnostics tests, powered by its ADx-ARMS and Super-ARMS technologies, will be made available in Hong Kong and Macau.

The real-time PCR-based test is designed to identify EGFR mutations in circulating tumor DNA in plasma samples.

Amoy will supply its CD95 IHC and CpG2 qPCR kits to develop a companion diagnostic for Canbridge's lead product targeting recurrent glioblastoma multiforme.

The firm's ROS1 gene fusion kit was approved as a companion diagnostic for Pfizer's Xalkori.

The test, which will be based on AmoyDx's proprietary real-time PCR technology, will identify cancer-associated mutations in the RAS gene family.

AmoyDx will develop and commercialize a series of oncology tests that use Illumina NGS technology, including the firm's TruSight Tumor 15 panel.

NEW YORK (GenomeWeb) — Chinese molecular diagnostics firm Amoy Diagnostics said today that four of its mutation analysis kits have received CE marking.

NEW YORK (GenomeWeb) – MoBiTec today announced a deal for the distribution of Amoy Diagnostics products in Germany.

NEW YORK (GenomeWeb) – Chinese molecular diagnostics firm Amoy Diagnostics this week announced it has received regulatory approval from the China Food and Drug Administration for two in vitro diagnostics kits.
The firm also said that the kits obtained CE marking in Europe.

Pages

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.